Tareq Al Baghdadi, MD
Medical Oncology · Ypsilanti, MINPI 1861515546
Payments from drug & device makers
Across 253 payments — averaging $4789.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$585K
- E.r. Squibb & Sons, L.L.C.$138K
- Genentech, Inc.$127K
- Janssen Research & Development, LLC$69K
- AstraZeneca$61K
- Incyte Corporation$56K
- plus $176K from 22 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 14 | $584,939 |
| E.r. Squibb & Sons, L.L.C. | 20 | $138,300 |
| Genentech, Inc. | 21 | $126,772 |
| Janssen Research & Development, LLC | 12 | $68,621 |
| AstraZeneca | 28 | $60,578 |
| Incyte Corporation | 11 | $56,115 |
| Pfizer | 10 | $42,098 |
| GSK | 10 | $41,721 |
| Eli Lilly | 3 | $22,293 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $17,484 |
| Lilly USA, LLC | 4 | $12,000 |
| Genentech USA, Inc. | 5 | $6,444 |
| AbbVie | 12 | $5,927 |
| Gilead(2 entities) | 4 | $4,922 |
| Johnson & Johnson(2 entities) | 4 | $4,789 |
| Genmab U.S., Inc. | 3 | $3,505 |
| Sobi, Inc | 2 | $3,219 |
| Bristol Myers Squibb | 4 | $2,883 |
| Morphosys, US Inc. | 1 | $2,655 |
| Janssen Scientific Affairs, LLC | 2 | $1,830 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Daiichi Sankyo Inc. | 3 | $1,110 |
| Merck | 68 | $815 |
| Astellas Pharma US Inc | 1 | $500 |
| Beigene, Ltd. | 1 | $450 |
| Athenex Pharmaceutical Division, LLC | 1 | $150 |
| Tempus AI, Inc | 1 | $73 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
How this compares
$1,211,761 in reported general payments places this provider in the 75th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Ypsilanti
- Philip StellaYpsilanti$1.2M
- Elie DibYpsilanti$240K
- Patricia Lo RussoDetroit$24.6M
- Manish SharmaGrand Rapids$19M
- Moshe TalpazAnn Arbor$13.7M
- Shirish GadgeelDetroit$11M
- Zachery ReichertAnn Arbor$10.6M
- Ammar SukariDetroit$8.4M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.